How effective is Erlotinib for lung cancer?

erlotinib is a relatively effective treatment of lung cancer. It is used primarily for lung cancer that is not in a small cell, the most common diversity. Studies have shown that the survival rate in patients taking drugs is higher than in patients who receive placebo. Research has also shown that the drug seems to be effective for women and can reduce the chances of dying due to lung cancer by 26 percent. Some patients respond to the drug, although they have previously used a medicine that works on the same basic principle.

Research by Erlotinib for lung cancer has shown that the drug improves the level of patient survival compared to placebo. After one year of treatment, 31 percent of patients who use erlotinib survive, while only 22 percent of patients survive. Studies like this often do not test erlotinib against alternative treatment of lung cancer, only unnecessary placebo. Scientists have also found that the cancer procedure slower for those who use erlotinib for lung cancer. In spite of these positIV results are recommended by Erlotinib in lung cancer only as an alternative to docetaxel or in patients who do not respond to other treatment.

Erlotinib patients usually do not experience cancer progression for 2.2 months compared to 1.8 months in placebo patients. The use of Erlotinib for lung cancer also also fights with some more common symptoms of the condition. Patients taking drugs are experiencing coughing, chest pain and breathing problems.

Erlotinib for lung cancer works by blocking receptors responsible for growth and multiplication of affected cells. The epidermal growth factor receptors take an epidermal growth factor that causes a chemical reaction that causes tumor growth. The drug blocks these receptors found in most patients tumors. Filling in the receptor, the ATM prevents the epidermal growth factor in the help of tumor growth and spread. Studies also confirmedthat some patients taking similar medicines for lung cancer can be able to switch to erlotinib when the old drug loses its efficiency.

Studies also found a strange trend in patients who respond better to the drug. For example, more women than men respond positively to the drug. Asians were also identified as another group that responds better to the drug in multiple scientific studies. It also helps if patients using Erlotinib have never smoked for lung cancer.